News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
375,813 Results
Type
Article (18394)
Company Profile (307)
Press Release (357112)
Section
Business (111487)
Career Advice (429)
Deals (21533)
Drug Delivery (51)
Drug Development (61699)
Employer Resources (52)
FDA (9287)
Job Trends (7618)
News (202165)
Policy (16926)
Tag
Academia (1246)
Alliances (28378)
Alzheimer's disease (995)
Approvals (9241)
Artificial intelligence (97)
Bankruptcy (191)
Best Places to Work (6725)
Biotechnology (251)
Breast cancer (140)
Cancer (1054)
Cardiovascular disease (86)
Career advice (374)
CAR-T (78)
Cell therapy (237)
Clinical research (49521)
Collaboration (338)
Compensation (140)
COVID-19 (1382)
C-suite (89)
Cystic fibrosis (77)
Data (1173)
Diabetes (115)
Diagnostics (2956)
Earnings (46544)
Events (60692)
Executive appointments (266)
FDA (9766)
Funding (332)
Gene therapy (176)
GLP-1 (376)
Government (1926)
Healthcare (9778)
Infectious disease (1436)
Inflammatory bowel disease (105)
IPO (11347)
Job creations (1233)
Job search strategy (334)
Layoffs (210)
Legal (2919)
Lung cancer (143)
Lymphoma (71)
Manufacturing (115)
Medical device (6179)
Medtech (6181)
Mergers & acquisitions (10351)
Metabolic disorders (322)
Neuroscience (1265)
NextGen Class of 2024 (2934)
Non-profit (1376)
Northern California (1300)
Obesity (186)
Opinion (132)
Parkinson's disease (76)
Patents (85)
People (31408)
Phase I (16512)
Phase II (22488)
Phase III (15515)
Pipeline (447)
Postmarket research (1271)
Preclinical (6774)
Radiopharmaceuticals (221)
Rare diseases (227)
Real estate (2108)
Regulatory (13018)
Research institute (1205)
Southern California (1147)
Startups (2238)
United States (10922)
Vaccines (247)
Weight loss (117)
Date
Today (34)
Last 7 days (566)
Last 30 days (2112)
Last 365 days (27077)
2024 (26417)
2023 (29974)
2022 (36152)
2021 (38046)
2020 (34017)
2019 (23992)
2018 (17744)
2017 (19641)
2016 (17036)
2015 (20753)
2014 (15137)
2013 (11197)
2012 (11471)
2011 (12022)
2010 (11392)
Location
Africa (282)
Arizona (77)
Asia (25989)
Australia (5583)
California (2925)
Canada (1147)
China (231)
Colorado (116)
Connecticut (138)
Europe (50351)
Florida (368)
Georgia (95)
Illinois (192)
Indiana (117)
Japan (67)
Maryland (405)
Massachusetts (2334)
Michigan (72)
Minnesota (141)
New Jersey (860)
New York (802)
North Carolina (549)
Northern California (1300)
Ohio (94)
Pennsylvania (632)
South America (446)
Southern California (1147)
Texas (386)
Washington State (338)
375,813 Results for "antisense therapeutics limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics
Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
May 28, 2024
·
2 min read
Business
Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
March 20, 2024
·
4 min read
Press Releases
Antisense and RNAi Therapeutics Market Size to Surge USD 30.03 Bn by 2033: 19.12% CAGR Growth Outlook
August 7, 2024
·
14 min read
Press Releases
U.S. Antisense And RNAi Therapeutics Market Size to Hit USD 17.87 Bn by 2033
June 11, 2024
·
12 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Press Releases
EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand
July 9, 2024
·
3 min read
Genetown
Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicines
Alloy Therapeutics announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.
June 28, 2023
·
6 min read
Press Releases
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
August 15, 2024
·
6 min read
Press Releases
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
December 5, 2024
·
19 min read
Biotech Beach
BOLDEN THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS
Bolden Therapeutics, Inc. today announced the closing of their $1.5M pre-seed convertible note financing.
January 17, 2024
·
2 min read
1 of 37,582
Next
